In summary, we are conducting a prospective, single-center, single-arm phase Ib/II clinical trial to evaluate the efficacy and safety of HBOT combined with chemotherapy and immunotherapy in HER2-negative advanced or metastatic GC/GEJC. Here, ERBB2 is linked to gastric cancer.